REFILE-BRIEF-FDA Approves Regeneron's Dupixent For Children Aged 6-11 Yrs With Moderate-To-Severe Atopic Dermatitis
May 27, 2020 at 07:12 AM EDT
* FDA APPROVES DUPIXENT® (DUPILUMAB) AS FIRST BIOLOGIC MEDICINE FOR CHILDREN AGED 6 TO 11 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS